Experimental Triple-Drug cocktail targets tough melanoma
NCT ID NCT02721459
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 36 times
Summary
This early-phase trial tests a new drug called XL888 added to two standard melanoma drugs (vemurafenib and cobimetinib) for people with advanced BRAF-mutated melanoma that cannot be removed by surgery. The main goal is to find the safest dose of XL888 and see how well the combination is tolerated. Only 26 participants are enrolled, so the focus is on safety, not yet on effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XL888 (HSP90 inhibitor) combined with vemurafenib and cobimetinib
What this could lead to
If it works, this could point toward a more effective combination therapy for advanced melanoma that may help control the disease longer.
What could go wrong
This is a very early Phase 1 trial with only 26 participants, so it is primarily testing safety and dosing. The combination may cause significant side effects and may not prove effective in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.